Relay Therapeutics Reports Initial Clinical Data for Zovegalisib in Vascular Anomalies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy RLAY?
Source: Newsfilter
- Initial Efficacy Data: In the ongoing Phase 2 ReInspire trial, zovegalisib demonstrated a 60% volumetric response rate at the 100mg BID dose, with 89% of patients reporting clinical improvement at 12 weeks, indicating its potential in treating vascular anomalies.
- Safety and Tolerability: Among 32 patients, none discontinued treatment due to adverse events, and the rates of treatment-related adverse events were proportional to dose, highlighting the long-term safety profile of zovegalisib.
- Expanded Dose Selection: The company has opened expansion cohorts for adults and adolescents at 400mg QD and 300mg BID, aiming to further validate the efficacy and safety of zovegalisib to support its application in vascular anomaly treatment.
- Clinical Outcomes Demonstrated: Initial patient and clinician-reported outcomes showed that 71% of patients experienced clinical improvement in pain symptoms, further validating zovegalisib's potential to enhance patient quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RLAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RLAY
Wall Street analysts forecast RLAY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.100
Low
13.00
Averages
14.75
High
17.00
Current: 12.100
Low
13.00
Averages
14.75
High
17.00
About RLAY
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Relay Therapeutics Reports Strong Early-Stage Data for Zovegalisib
- Clinical Trial Results: Relay Therapeutics' Zovegalisib demonstrated strong efficacy in early-stage trials for patients with vascular anomalies, with 60% of evaluable patients achieving a significant reduction in lesion volume within 12 weeks, and nearly all patients reporting symptom improvement, indicating a favorable safety profile suitable for long-term use.
- Patient Recruitment: The study enrolled 32 patients, with no adverse events reported, and all patients remained on treatment as of the latest data cut-off, showcasing the drug's good tolerability and potential market prospects.
- Breast Cancer Treatment Progress: Relay Therapeutics is advancing late-stage studies of Zovegalisib in breast cancer, with the FDA granting Breakthrough Therapy designation, further broadening its drug development pipeline and enhancing the company's competitiveness in cancer treatment.
- Positive Stock Reaction: Following the release of encouraging clinical data, Relay Therapeutics' shares jumped 10% in pre-market trading, reflecting strong market confidence in its drug development, with the stock gaining over 43% this year.
See More
Relay Therapeutics Reports Initial Clinical Results of Zovegalisib in Phase 2 Trial
- Clinical Trial Progress: Relay Therapeutics' ongoing Phase 2 ReInspire trial of Zovegalisib shows promising efficacy in patients with PIK3CA-driven vascular anomalies, with 60% of patients achieving volumetric lesion reduction at the 12-week assessment, indicating the potential of new targeted therapies.
- Significant Symptom Improvement: Nearly all patients experienced symptomatic improvements, with clinical benefits reported by 89% of investigators and 79% of patients, highlighting Zovegalisib's positive impact on quality of life for patients.
- Good Safety Profile: The interim safety analysis supports chronic dosing of Zovegalisib, with no treatment discontinuations due to adverse events, and common side effects were manageable and reversible, with no severe rash, stomatitis, or high-grade hyperglycemia reported.
- Broad Treatment Prospects: The study leader noted that these data demonstrate, for the first time, the promise of PI3Ka mutant-selective inhibition, which could change the treatment paradigm for this underserved population, while Zovegalisib is also being investigated in Phase 3 trials for other indications.
See More
Relay Therapeutics' Zovegalisib Shows Promising Mid-Stage Trial Results
- Clinical Trial Response Rate: In Relay Therapeutics' mid-stage trial for zovegalisib, approximately 60% of 20 evaluable patients achieved a volumetric response by 12 weeks, indicating significant potential for the drug in treating vascular anomalies and possibly enhancing the company's market position in this niche.
- Clinical Improvement Assessments: At Week 12, 89% and 79% of patients showed clinical improvement in IGIC and PGIC scores, respectively, reflecting the efficacy of zovegalisib in the patient population and potentially providing strong support for further clinical development.
- Dose Adjustment Outcomes: Among the 12 analyzed patients, 23% experienced dose reductions without any dose discontinuations, demonstrating good tolerability of the drug, which may offer flexibility for future treatment regimens.
- Expansion Dose Selection: The company has selected 400 mg QD and 300 mg BID as expansion doses, with patient enrollments for these cohorts currently underway, indicating the potential for further clinical development and market introduction of zovegalisib.
See More
Relay Therapeutics Reports Initial Clinical Data for Zovegalisib in Vascular Anomalies
- Initial Efficacy Data: In the ongoing Phase 2 ReInspire trial, zovegalisib demonstrated a 60% volumetric response rate at the 100mg BID dose, with 89% of patients reporting clinical improvement at 12 weeks, indicating its potential in treating vascular anomalies.
- Safety and Tolerability: Among 32 patients, none discontinued treatment due to adverse events, and the rates of treatment-related adverse events were proportional to dose, highlighting the long-term safety profile of zovegalisib.
- Expanded Dose Selection: The company has opened expansion cohorts for adults and adolescents at 400mg QD and 300mg BID, aiming to further validate the efficacy and safety of zovegalisib to support its application in vascular anomaly treatment.
- Clinical Outcomes Demonstrated: Initial patient and clinician-reported outcomes showed that 71% of patients experienced clinical improvement in pain symptoms, further validating zovegalisib's potential to enhance patient quality of life.
See More
Relay Therapeutics to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Relay Therapeutics is set to release its Q1 2023 earnings report on May 5 after market close, with consensus EPS estimated at -$0.36 and revenue expected at $4.65 million, reflecting a significant 39.5% year-over-year decline, indicating challenges in the current market environment.
- Earnings Forecast Analysis: Over the past three months, EPS estimates have seen six upward revisions with no downward adjustments, suggesting cautious optimism among analysts regarding the company's future performance, although the overall revenue outlook remains weak, potentially impacting investor confidence.
- Market Focus: Ahead of the earnings report, Relay Therapeutics has garnered attention for its discussions on first-line breast cancer strategies and Zovegalisib triplet data, which could provide new momentum for the company's future growth prospects.
- Industry Rating Dynamics: According to Seeking Alpha's quant ratings, Relay Therapeutics and TNGX are highlighted as top picks ahead of Q1 earnings, indicating a positive market sentiment towards their potential performance, despite the current financial data warranting close scrutiny.
See More
Relay Therapeutics Advances Zovegalisib into Phase 3 Trials for Breast Cancer
- Clinical Trial Advancement: Relay Therapeutics announced plans to move Zovegalisib in combination with Pfizer's Atirmociclib into Phase 3 trials for frontline treatment of PI3Ka-mutated HR+/HER2- metastatic breast cancer, expected to commence in early 2027, showcasing the company's ongoing innovation in precision medicine.
- Trial Design Details: The randomized Phase 3 trial will evaluate the combination of Zovegalisib with Atirmociclib and an aromatase inhibitor, with median progression-free survival as the primary endpoint and overall survival as the secondary endpoint, aiming to provide more effective treatment options and enhance clinical outcomes for patients.
- Drug Supply Agreement: Pfizer has agreed to supply Atirmociclib for the experimental arm in combination with Zovegalisib, while the control arm will use palbociclib, enhancing the feasibility and efficacy of the trial and further driving the market potential of the new drug.
- Patient Response Rates: In the ongoing ReDiscover study, 34 out of 69 enrolled patients were evaluable, achieving an objective response rate of 44%, with nearly 85% of patients experiencing tumor reduction, indicating Zovegalisib's potential effectiveness in treatment and laying the groundwork for future therapeutic strategies.
See More
Relay Therapeutics Reports Strong Early-Stage Data for Zovegalisib
- Clinical Trial Results: Relay Therapeutics' Zovegalisib demonstrated strong efficacy in early-stage trials for patients with vascular anomalies, with 60% of evaluable patients achieving a significant reduction in lesion volume within 12 weeks, and nearly all patients reporting symptom improvement, indicating a favorable safety profile suitable for long-term use.
- Patient Recruitment: The study enrolled 32 patients, with no adverse events reported, and all patients remained on treatment as of the latest data cut-off, showcasing the drug's good tolerability and potential market prospects.
- Breast Cancer Treatment Progress: Relay Therapeutics is advancing late-stage studies of Zovegalisib in breast cancer, with the FDA granting Breakthrough Therapy designation, further broadening its drug development pipeline and enhancing the company's competitiveness in cancer treatment.
- Positive Stock Reaction: Following the release of encouraging clinical data, Relay Therapeutics' shares jumped 10% in pre-market trading, reflecting strong market confidence in its drug development, with the stock gaining over 43% this year.
See More
Relay Therapeutics Reports Initial Clinical Results of Zovegalisib in Phase 2 Trial
- Clinical Trial Progress: Relay Therapeutics' ongoing Phase 2 ReInspire trial of Zovegalisib shows promising efficacy in patients with PIK3CA-driven vascular anomalies, with 60% of patients achieving volumetric lesion reduction at the 12-week assessment, indicating the potential of new targeted therapies.
- Significant Symptom Improvement: Nearly all patients experienced symptomatic improvements, with clinical benefits reported by 89% of investigators and 79% of patients, highlighting Zovegalisib's positive impact on quality of life for patients.
- Good Safety Profile: The interim safety analysis supports chronic dosing of Zovegalisib, with no treatment discontinuations due to adverse events, and common side effects were manageable and reversible, with no severe rash, stomatitis, or high-grade hyperglycemia reported.
- Broad Treatment Prospects: The study leader noted that these data demonstrate, for the first time, the promise of PI3Ka mutant-selective inhibition, which could change the treatment paradigm for this underserved population, while Zovegalisib is also being investigated in Phase 3 trials for other indications.
See More
Relay Therapeutics' Zovegalisib Shows Promising Mid-Stage Trial Results
- Clinical Trial Response Rate: In Relay Therapeutics' mid-stage trial for zovegalisib, approximately 60% of 20 evaluable patients achieved a volumetric response by 12 weeks, indicating significant potential for the drug in treating vascular anomalies and possibly enhancing the company's market position in this niche.
- Clinical Improvement Assessments: At Week 12, 89% and 79% of patients showed clinical improvement in IGIC and PGIC scores, respectively, reflecting the efficacy of zovegalisib in the patient population and potentially providing strong support for further clinical development.
- Dose Adjustment Outcomes: Among the 12 analyzed patients, 23% experienced dose reductions without any dose discontinuations, demonstrating good tolerability of the drug, which may offer flexibility for future treatment regimens.
- Expansion Dose Selection: The company has selected 400 mg QD and 300 mg BID as expansion doses, with patient enrollments for these cohorts currently underway, indicating the potential for further clinical development and market introduction of zovegalisib.
See More
Relay Therapeutics Reports Initial Clinical Data for Zovegalisib in Vascular Anomalies
- Initial Efficacy Data: In the ongoing Phase 2 ReInspire trial, zovegalisib demonstrated a 60% volumetric response rate at the 100mg BID dose, with 89% of patients reporting clinical improvement at 12 weeks, indicating its potential in treating vascular anomalies.
- Safety and Tolerability: Among 32 patients, none discontinued treatment due to adverse events, and the rates of treatment-related adverse events were proportional to dose, highlighting the long-term safety profile of zovegalisib.
- Expanded Dose Selection: The company has opened expansion cohorts for adults and adolescents at 400mg QD and 300mg BID, aiming to further validate the efficacy and safety of zovegalisib to support its application in vascular anomaly treatment.
- Clinical Outcomes Demonstrated: Initial patient and clinician-reported outcomes showed that 71% of patients experienced clinical improvement in pain symptoms, further validating zovegalisib's potential to enhance patient quality of life.
See More
Relay Therapeutics to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Relay Therapeutics is set to release its Q1 2023 earnings report on May 5 after market close, with consensus EPS estimated at -$0.36 and revenue expected at $4.65 million, reflecting a significant 39.5% year-over-year decline, indicating challenges in the current market environment.
- Earnings Forecast Analysis: Over the past three months, EPS estimates have seen six upward revisions with no downward adjustments, suggesting cautious optimism among analysts regarding the company's future performance, although the overall revenue outlook remains weak, potentially impacting investor confidence.
- Market Focus: Ahead of the earnings report, Relay Therapeutics has garnered attention for its discussions on first-line breast cancer strategies and Zovegalisib triplet data, which could provide new momentum for the company's future growth prospects.
- Industry Rating Dynamics: According to Seeking Alpha's quant ratings, Relay Therapeutics and TNGX are highlighted as top picks ahead of Q1 earnings, indicating a positive market sentiment towards their potential performance, despite the current financial data warranting close scrutiny.
See More
Relay Therapeutics Advances Zovegalisib into Phase 3 Trials for Breast Cancer
- Clinical Trial Advancement: Relay Therapeutics announced plans to move Zovegalisib in combination with Pfizer's Atirmociclib into Phase 3 trials for frontline treatment of PI3Ka-mutated HR+/HER2- metastatic breast cancer, expected to commence in early 2027, showcasing the company's ongoing innovation in precision medicine.
- Trial Design Details: The randomized Phase 3 trial will evaluate the combination of Zovegalisib with Atirmociclib and an aromatase inhibitor, with median progression-free survival as the primary endpoint and overall survival as the secondary endpoint, aiming to provide more effective treatment options and enhance clinical outcomes for patients.
- Drug Supply Agreement: Pfizer has agreed to supply Atirmociclib for the experimental arm in combination with Zovegalisib, while the control arm will use palbociclib, enhancing the feasibility and efficacy of the trial and further driving the market potential of the new drug.
- Patient Response Rates: In the ongoing ReDiscover study, 34 out of 69 enrolled patients were evaluable, achieving an objective response rate of 44%, with nearly 85% of patients experiencing tumor reduction, indicating Zovegalisib's potential effectiveness in treatment and laying the groundwork for future therapeutic strategies.
See More
